Uric acid
EstablishedUric acid causes gout via crystal deposition and is also a key pretreatment risk marker for tumor lysis syndrome in oncology.
Uric acid buildup causes gout, a painful joint condition, and separately, it's a key blood test doctors check before starting chemotherapy for certain aggressive cancers, since rapid tumor cell breakdown can release dangerous amounts of uric acid all at once.
Uric acid is the final breakdown product of purine metabolism; elevated levels (hyperuricemia) cause gout through monosodium urate crystal deposition in joints and connect directly to the tumor lysis syndrome discussion referenced elsewhere in this biomarker set.
Elevated uric acid supports a gout diagnosis in a patient with characteristic joint symptoms, though definitive diagnosis requires joint fluid analysis showing urate crystals, since uric acid levels don't perfectly correlate with acute gout flares (some patients flare at normal levels, others have high levels without ever developing gout).
Measured via enzymatic colorimetric assay; uric acid is also a key pretreatment risk marker for tumor lysis syndrome (alongside potassium, phosphate, and LDH, discussed earlier in this set) in patients starting chemotherapy for bulky, fast-growing cancers, particularly high-grade lymphomas and leukemias.
Urate-lowering therapy (allopurinol, febuxostat) is used for chronic gout management, targeting uric acid levels below a specific threshold (typically <6 mg/dL) to prevent crystal formation; rasburicase (a uric acid-degrading enzyme) is used prophylactically in high tumor lysis syndrome risk patients starting chemotherapy.
Connects directly to the LDH/tumor lysis syndrome discussion elsewhere in this set as part of the same pretreatment risk panel.
- General rheumatology and oncology reference literature on uric acid in gout management and tumor lysis syndrome risk assessment.